Rate Video

GU Cancers 2019 | Nrf2 inhibitors to overcome chemoresistance

Simon Crabb • 15 Feb 2019

GU Cancers 2019

Bladder Cancer Genitourinary Cancer Cisplatin

Simon Crabb, MBBS, MRCP, PhD, of the University of Southampton, Southampton, UK, talks about targeting Nrf2 signaling pathways to overcome resistance to chemotherapeutic agents in bladder cancer. This video was taken at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.

Beyond cancer treatment: nurse specialists in the clinic

Key prostate cancer news from GU 2019

Simon Crabb • 15 Feb 2019

Awaiting key results for enzalutamide and apalutamide in nmCRPC

ProCAID: Investigating the use of AZD5363 alongside chemotherapy in mCRPC

Simon Crabb • 15 Feb 2019

Related Videos

Updates on MRx0518 + pembro in patients with resistance to therapy

Alex Stevenson • 27 Nov 2020

IMvigor130: patient-reported outcomes by the addition of atezolizumab to PBC in mUC

Aris Bamias • 23 Nov 2020

Treatment options for mUC following chemo-immunotherapy failure

Aris Bamias • 23 Nov 2020

Optimising treatment for advanced urothelial cancer: combination, maintenance or sequencing?

Arlene Siefker-Radtke • 14 Oct 2020